The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
Feedback I provided:
"It was good to have a clearer understanding of the business going forward with regards to collaboration, funds and research. Press releases from the company generally very negative and ...... More thorough and more regular updates to investors are advised ............ It was good to learn that further cash will not be sought after ...... It was encouraging to learn that you will be announcing results from pharma/biotech collaboration at the earliest this year in addition to an elaboration of the Fuson pharma deal announced recently.
It was always a bad sign when the founder of ReNeuron John Sinden, left the company in 2019 just as positive RP results were announced...... he clearly wasn't convinced to have left the company at that point. He had been very excited about Exosomes, see below the announcement made in 2013. So 9 years later this is now becoming a priority? As Olav mentioned if they had known that exosomes worked so well they would have used them in the Stroke programme. Could this be the new deal that's being contemplated with Fosun? Do they really have proprietary information on exosomes, superior patents ......is anyone a patent expert here ? Sinden has a new company working on this 'Glialign' using CTX and exosomes. What does this all mean?
Guildford, UK, 19 April 2013: ReNeuron announces that later today it will be presenting important new pre-clinical data on the potential mechanisms by which its lead CTX stem cell line exerts its therapeutic effects. Dr John Sinden, Chief Scientific Officer of ReNeuron, said:
“The data we are presenting today is exciting, both scientifically and commercially. The results provide further knowledge and validation of the therapeutic potential of our lead CTX cell therapy candidate. In addition, the field of exosome research is growing fast and, having filed multiple new patent applications, we are well-placed to exploit its future potential because CTX cells have the capacity to become an efficient and potentially very valuable “producer” cell line for exosome-based diagnostic products or therapies.”
Thank you Clivealive for bringing back a reflective tone to the recent posts, like you I have been buying shares in Reneuron since 2015, and like you have been topping up but never selling. As a scientist it has been very reassuring to have joined this group a while back. It has been a knowledgeable arena to tap into and the core die hard participants have an excellent grasp of the science as well as investment information and knowledge, so thank you all !!! Amongst so many stem cell companies that have failed, I've always believed that Reneuron would be one of the successful ones. Unfortunately their Stroke programme did not reach the targets originally planned, but current projects hold much promise. Good luck to all die hards in the coming years.
Some of us have followed this company since it spun out from the Institute of Psychiatry KCL in the 1990 by founder Dr John Sinden who finally left Reneuron as Chief Scientific Officer last year 2019. Some may even have been supporting this company since it floated in the AIMS market in 2005 and most since 2016 following Woodford. There is no doubt that it has been a hard road for both the company and for investors, each time with huge fluctuations, anticipation and also dispair. Michael Hunt and John Sinden had both been a good constant in the company, but why did the founder of the company leave at such an exciting time ?
Another question, why is the CEO (since 2014) being paid a salary £539,000 despite falling share price and when the company has only one years of funding left in the bank. Surely the CEO should have more skin in the game if all early investors have?
Of course shares can be diluted if the company needs more money after a year but only at the expense of those who have supported the company through thick and thin, believing in the science when others sold out. I still believe in the science and believe this company will go far, but I don't believe that this is the way the company should be repaying share holders, our shares have been diluted enough.
It indeed appears to be a particularly exciting times for RENE with regards to the Retinitis pigments study given the recents results published by 'Icyte' its main competitor. And of course with regards to any potential exosome deals.
I would like to have seen share holders have more of a voice, if RENE are ready this please consider these questions!
Hi Chester18,
jCYTE are ReNeuron's only real competitor both using stem cell technology, the recent results mean jCyte will be ahead in the race to take market share well before RENE product is out, RENE need to get their act together and speed up. US biotech is supported by VC's in the way we can't imagine, hence jCyte a private company ready to steal RENE efforts. Perhaps the Johnson administration should put their money where their mouth is and help out such amazing companies rather than slaughtering them to the US yet again!
Haplo
Here are the results Onceaday......Looks like ReNeurons competitors are doing well with their phase 2 results:
" jCyte Inc. Announces Promising Phase 2b Results of jCell Therapy in Retinitis Pigmentosa
Phase 2b results show that treatment with jCell was well-tolerated and demonstrated encouraging evidence of potential benefit in patients as an investigational treatment for retinitis pigmentosa agnostic to genetic subtype
Based on these results, jCyte plans to initiate a pivotal study in 2021
jCell is a first-in-class investigational treatment which has received Regenerative Medicine Advanced Therapy (RMAT) designation from the US Food and Drug Administration (FDA), and Orphan Drug designation from both the FDA and the European Medicines Agency (EMA)
Data presented at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting on Saturday, July 25 "
Here's the link:
2020https://www.businesswire.com/news/home/20200727005222/en/jCyte-Announces-Promising-Phase-2b-Results-jCell
There is a clear advantage to stem cell therapy compared to small molecule drug development, the eye watering costs of getting from phaseI- phaseIII clinical trials and so to market is hugely reduced from billions to millions. As with RENE an orphan drug status is also a strong positive as regulatory authorities favour this for fast tracking. If and only if phase III gets through successfully, then RENE is on its road to getting its billion/s dollar valuation. Once it does, I hope it does not sell off to an American company- sadly this is how many great UK Biotech start-ups have ended up.
Such a discrepancy on some sites could put people off from investing as a Mcap of 100M is a bargain for this stock where as 200M plus would be more like what is should be. At this level the share price would be more like 600 not 300! The Mcap on Yahoo this moment is 203M which is clearly incorrect.